Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 212

Sort by

Sort Order Select

Journal Articles

Clinical and biological characteristics of autoimmune neutropenia in adults according to the presence of anti-granulocyte antibodies: A multicenter retrospective Study of 79 cases

Dorann Bartebin, Jerome Hadjadj, Laure Croisille, Emilie Letoriellec, Corinne Haioun, Delphine Gobert, Antoine Dossier, Olivier Fain, Matthieu Mahevas, Bertrand Godeau, Karim Sacré, Marc Michel, Etienne Crickx

Blood (2025) 146 (Supplement 1): 2984.

https://doi.org/10.1182/blood-2025-2984

Published: 2025

Journal Articles

PlatΤform: A multicenter, multi-arm, academic platform trial evaluating novel agents and combinations in relapsed or refractory peripheral T-cell lymphomas

David Sibon, Doriane Cavalieri, Mad-Helenie Elsensohn, Eve Gehlkopf, Delphine Leduc, Corinne Haioun, François Lemonnier

Blood (2025) 146 (Supplement 1): 3657.

https://doi.org/10.1182/blood-2025-3657

Published: 2025

Journal Articles

Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries

Gabriel Brisou, Aurelien Belot, Emmanuel Bachy, Herve Ghesquieres, François-Xavier Gros, Krimo Bouabdallah, Guillaume Cartron, Roberta Di Blasi, Roch Houot, Cedric Rossi, Amandine Durand, Fabien Le Bras, Corinne Haioun, Thomas Gastinne, Remy Dulery, Pierre Bories, Fabrice Jardin, Blandine Guffroy, Luc-Matthieu Fornecker, Cristina Castilla-Llorente, Gandhi Damaj, Franck Morschhauser, Michael Loschi, Stephanie Guidez, Choquet Sylvain, Aline Schmidt, Laurianne Drieu La Rochelle, Marie-Thérèse Rubio, Sylvain Carras, Jacques-Olivier Bay, Adrien Chauchet, Magalie Joris, Ludovic Fouillet, Laure Lebras, Julie Abraham, Fontanet Bijou, Olivier Hermine, Antoine Bonnet, Justine Decroocq, Sandy Amorim, Nadine Morineau, Pauline Lionne, Sophie Dennetiere, Laura Herbreteau, Bernard Drenou, Launay Vincent, Gaelle Olivier, Gaëlle Labouré, Olivier Fitoussi, Christophe Fruchart, Cecile Leyronnas, Fanny Cherblanc, Elodie Gat, Benoit Tessoulin

Blood (2025) 146 (Supplement 1): 2764.

https://doi.org/10.1182/blood-2025-2764

Published: 2025

Journal Articles

Daratumumab can lead to long-lasting remissions in patients with refractory immune thrombocytopenia but with a high incidence of severe infections

Blood (2025) 146 (Supplement 1): 4818.

https://doi.org/10.1182/blood-2025-4818

Published: 2025

Journal Articles

Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa

Blood (2024) 144 (Supplement 1): 575.

https://doi.org/10.1182/blood-2024-202446

Published: 2024

Journal Articles

Long-Term Follow-up Study of Patients Aged 80 Years or Older Treated By Attenuated Chemotherapy Mini-CHOP Plus Anti-CD20 for DLBCL, Update of the LNH03-7B and LNH09-7B Lysa Trials

Jean-Marie Michot, Cédric Portugues, Lucie Oberic, Fabrice Jardin, Vincent Delwail, Vincent Camus, Franck Morschhauser, Catherine Thieblemont, Corinne Haioun, Frederic Peyrade, Hervé Tilly

Blood (2024) 144 (Supplement 1): 4467.

https://doi.org/10.1182/blood-2024-202588

Published: 2024

Journal Articles

Cold Autoimmune Hemolytic Anemia Secondary to Mycoplasma Pneumoniae Infection in Adults: Results from a Large French Observational Study (MYCOLD study)

Blood (2024) 144 (Supplement 1): 3840.

https://doi.org/10.1182/blood-2024-204053

Published: 2024

Journal Articles

Senior-IPI: An Easily Applicable and Meaningful Prognostic Index for First-Line LBCL Patients Older Than 80 Years Treated with Age-Adapted Immunochemotherapy

Sydney Dubois, Fanny Cherblanc, Aurelien Belot, Lucie Oberic, Herve Ghesquieres, Corinne Haioun, Hervé Tilly, Jean-Philippe Jais, Fabrice Jardin

Blood (2024) 144 (Supplement 1): 649.

https://doi.org/10.1182/blood-2024-203926

Published: 2024

Journal Articles

Single-Cell Atlas of Diffuse Large B-Cell Lymphoma Reveals Integrated Malignant B Cell and Tumor Microenvironment Characteristics Associated with Clinical Response

Blood (2024) 144 (Supplement 1): 1597.

https://doi.org/10.1182/blood-2024-209815

Published: 2024

Journal Articles

Optical Genome Mapping Provides New Molecular Insights in High-Risk Mantle Cell Lymphoma: A Lysa Study

Blood (2023) 142 (Supplement 1): 6107.

https://doi.org/10.1182/blood-2023-173815

Published: 2023

Journal Articles

Validation of POD24 As a Robust Early Clinical End Point of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials

Blood (2023) 142 (Supplement 1): 299.

https://doi.org/10.1182/blood-2023-173615

Published: 2023

Journal Articles

A Single Cell Atlas of Diffuse Large B Cell Lymphomas Reveals Distinct Cellular States Predictive of Outcomes

Blood (2023) 142 (Supplement 1): 848.

https://doi.org/10.1182/blood-2023-173929

Published: 2023

Journal Articles

A Simplified IPI Including BCL2 Identifies IPI 3 Patients with Poor Prognosis - a GLA/ Dshnhl and Lysa Collaboration

Blood (2023) 142 (Supplement 1): 191.

https://doi.org/10.1182/blood-2023-184611

Published: 2023

Journal Articles

Impact of Brentuximab Vedotin in Patients with Breast Implant-Associated Anaplastic Large Cell Lymphoma with Capsule Infiltration Requiring Chemotherapy

Blood (2023) 142 (Supplement 1): 4439.

https://doi.org/10.1182/blood-2023-188896

Published: 2023

Journal Articles

R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG

Blood (2023) 142 (Supplement 1): 435.

https://doi.org/10.1182/blood-2023-172951

Published: 2023

Journal Articles

The CD38/CD3xCD28 Trispecific Antibody (SAR442257) Potentially Represents a Novel Therapeutic Strategy for Peripheral T-Cell Lymphomas

Aurélie Dupuy, Laura Pelletier, Jerome Giustiniani, Peter Kim, Kamlesh Bisht, Hongfang Wang, Helgi J. Van de Velde, Corinne Haioun, Philippe Gaulard, Nicolas Ortonne

Blood (2023) 142 (Supplement 1): 4384.

https://doi.org/10.1182/blood-2023-189088

Published: 2023

Journal Articles

Glofitamab (Glofit) Plus R-CHOP Has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined As High Risk By Circulating Tumor DNA (ctDNA) Dynamics: Preliminary Safety and Efficacy Results

Blood (2023) 142 (Supplement 1): 858.

https://doi.org/10.1182/blood-2023-173953

Published: 2023

Journal Articles

Combining PET/CT and Ctdna Assessments at 6 Months from Induction Treatment Better Predicts Outcome in Previously Untreated Patients with Follicular Lymphoma: A Relevance Ancillary Lysa Study

Blood (2023) 142 (Supplement 1): 170.

https://doi.org/10.1182/blood-2023-178030

Published: 2023

Journal Articles

Results of the Phase II of Epirchop Study, Evaluating the Efficacy of Tazemetostat in Combination with R-CHOP in Elderly Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): A Lysa Study

Clementine Sarkozy, Thierry Jo Molina, Roch Houot, Sydney Dubois, Gian Matteo Pica, Philippe Ruminy, Charles Herbaux, Thomas Gastinne, Corinne Haioun, Stephanie Guidez, Christophe Bonnet, Marc Andre, Liana Vereseza, Choquet Sylvain, Loic Ysebaert, Emmanuel Bachy, Fabrice Jardin, Franck Morschhauser, Vincent Ribrag

Blood (2023) 142 (Supplement 1): 853.

https://doi.org/10.1182/blood-2023-174607

Published: 2023

Journal Articles

Identification and Clinical Characterization of CNS Relapse in DLBCL Patients across 19 Prospective Phase 2 and 3 Trials - a GLA/ DSHNHL and LYSA Collaboration

Blood (2023) 142 (Supplement 1): 71.

https://doi.org/10.1182/blood-2023-178815

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Clinical and biological characteristics of autoimmune neutropenia in adults according to the presence of anti-granulocyte antibodies: A multicenter retrospective Study of 79 cases

PlatΤform: A multicenter, multi-arm, academic platform trial evaluating novel agents and combinations in relapsed or refractory peripheral T-cell lymphomas

Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries

Daratumumab can lead to long-lasting remissions in patients with refractory immune thrombocytopenia but with a high incidence of severe infections

Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa

Long-Term Follow-up Study of Patients Aged 80 Years or Older Treated By Attenuated Chemotherapy Mini-CHOP Plus Anti-CD20 for DLBCL, Update of the LNH03-7B and LNH09-7B Lysa Trials

Cold Autoimmune Hemolytic Anemia Secondary to Mycoplasma Pneumoniae Infection in Adults: Results from a Large French Observational Study (MYCOLD study)

Senior-IPI: An Easily Applicable and Meaningful Prognostic Index for First-Line LBCL Patients Older Than 80 Years Treated with Age-Adapted Immunochemotherapy

Single-Cell Atlas of Diffuse Large B-Cell Lymphoma Reveals Integrated Malignant B Cell and Tumor Microenvironment Characteristics Associated with Clinical Response

Optical Genome Mapping Provides New Molecular Insights in High-Risk Mantle Cell Lymphoma: A Lysa Study

Validation of POD24 As a Robust Early Clinical End Point of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials

A Single Cell Atlas of Diffuse Large B Cell Lymphomas Reveals Distinct Cellular States Predictive of Outcomes

A Simplified IPI Including BCL2 Identifies IPI 3 Patients with Poor Prognosis - a GLA/ Dshnhl and Lysa Collaboration

Impact of Brentuximab Vedotin in Patients with Breast Implant-Associated Anaplastic Large Cell Lymphoma with Capsule Infiltration Requiring Chemotherapy

R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG

The CD38/CD3xCD28 Trispecific Antibody (SAR442257) Potentially Represents a Novel Therapeutic Strategy for Peripheral T-Cell Lymphomas

Glofitamab (Glofit) Plus R-CHOP Has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined As High Risk By Circulating Tumor DNA (ctDNA) Dynamics: Preliminary Safety and Efficacy Results

Combining PET/CT and Ctdna Assessments at 6 Months from Induction Treatment Better Predicts Outcome in Previously Untreated Patients with Follicular Lymphoma: A Relevance Ancillary Lysa Study

Results of the Phase II of Epirchop Study, Evaluating the Efficacy of Tazemetostat in Combination with R-CHOP in Elderly Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): A Lysa Study

Identification and Clinical Characterization of CNS Relapse in DLBCL Patients across 19 Prospective Phase 2 and 3 Trials - a GLA/ DSHNHL and LYSA Collaboration

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only